156 related articles for article (PubMed ID: 26115187)
1. Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Fernández-Rodríguez C; Besses C
Br J Haematol; 2016 Feb; 172(4):639-42. PubMed ID: 26115187
[No Abstract] [Full Text] [Related]
2. JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
Barosi G; Klersy C; Villani L; Bonetti E; Catarsi P; Poletto V; Campanelli R; Impera S; Latagliata R; Viarengo G; Carolei A; Massa M; Musso M; Crescimanno A; Gale RP; Rosti V
Leukemia; 2016 Aug; 30(8):1772-5. PubMed ID: 26975727
[No Abstract] [Full Text] [Related]
3. Effect of mutation order on myeloproliferative neoplasms.
Ortmann CA; Kent DG; Nangalia J; Silber Y; Wedge DC; Grinfeld J; Baxter EJ; Massie CE; Papaemmanuil E; Menon S; Godfrey AL; Dimitropoulou D; Guglielmelli P; Bellosillo B; Besses C; Döhner K; Harrison CN; Vassiliou GS; Vannucchi A; Campbell PJ; Green AR
N Engl J Med; 2015 Feb; 372(7):601-612. PubMed ID: 25671252
[TBL] [Abstract][Full Text] [Related]
4. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.
Passamonti F; Rumi E; Pietra D; Della Porta MG; Boveri E; Pascutto C; Vanelli L; Arcaini L; Burcheri S; Malcovati L; Lazzarino M; Cazzola M
Blood; 2006 May; 107(9):3676-82. PubMed ID: 16373657
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
[TBL] [Abstract][Full Text] [Related]
6. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
[TBL] [Abstract][Full Text] [Related]
8. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.
Boklund TI; Snyder J; Gudmand-Hoeyer J; Larsen MK; Knudsen TA; Eickhardt-Dalbøge CS; Skov V; Kjær L; Hasselbalch HC; Andersen M; Ottesen JT; Stiehl T
Front Immunol; 2024; 15():1384509. PubMed ID: 38846951
[TBL] [Abstract][Full Text] [Related]
9. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
[No Abstract] [Full Text] [Related]
10. Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.
Gerlach MM; Lundberg P; Halter J; Arranto C; Wenzel F; Dirnhofer S; Tzankov A
Leuk Lymphoma; 2018 Aug; 59(8):1994-1997. PubMed ID: 29199511
[No Abstract] [Full Text] [Related]
11. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.
Theocharides A; Passweg JR; Medinger M; Looser R; Li S; Hao-Shen H; Buser AS; Gratwohl A; Tichelli A; Skoda RC
Haematologica; 2008 Dec; 93(12):1890-3. PubMed ID: 18790796
[TBL] [Abstract][Full Text] [Related]
12. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Larsen TS; Pallisgaard N; de Stricker K; Møller MB; Hasselbalch HC
Hematology; 2009 Feb; 14(1):11-5. PubMed ID: 19154659
[TBL] [Abstract][Full Text] [Related]
13. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC
J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
[TBL] [Abstract][Full Text] [Related]
16. Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2
Fukutsuka K; Iioka F; Maekawa F; Nakagawa M; Kishimori C; Hayashida M; Tagawa S; Akasaka T; Honjo G; Ohno H
J Clin Exp Hematop; 2021 Jun; 61(2):114-119. PubMed ID: 33994432
[TBL] [Abstract][Full Text] [Related]
17. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
Lasho TL; Mesa R; Gilliland DG; Tefferi A
Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
[No Abstract] [Full Text] [Related]
18. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
19. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
20. Genetics: Myeloproliferative neoplasms—order of mutations counts!
Hutchinson L
Nat Rev Clin Oncol; 2015 Apr; 12(4):187. PubMed ID: 25734632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
